BioNTech’s Sean Marett explains Genentech deal rationale

November 24, 2016 Christoph Graener

Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm’s recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.



Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Sean Marett – COO, BioNTech


Previous Article
Freshly-appointed Auspherix CEO highlights new antibiotic class
Freshly-appointed Auspherix CEO highlights new antibiotic class

Auspherix’s newly-appointed CEO talks about the science behind the company’s gram-negative targeting new an...

Next Article
Janssen focuses cardiometabolic R&D on prevention, cure and interception

With readouts in trials of key drugs Invokana and Xarelto coming, Dr. James F. List of Janssen is also look...